FR2594683A1 - Skin tests for anaesthetics - Google Patents
Skin tests for anaesthetics Download PDFInfo
- Publication number
- FR2594683A1 FR2594683A1 FR8602561A FR8602561A FR2594683A1 FR 2594683 A1 FR2594683 A1 FR 2594683A1 FR 8602561 A FR8602561 A FR 8602561A FR 8602561 A FR8602561 A FR 8602561A FR 2594683 A1 FR2594683 A1 FR 2594683A1
- Authority
- FR
- France
- Prior art keywords
- substance
- anesthetic
- tip
- gel
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 230000003444 anaesthetic effect Effects 0.000 title claims abstract description 26
- 229940124326 anaesthetic agent Drugs 0.000 title abstract 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 12
- 229940035674 anesthetics Drugs 0.000 claims description 12
- 239000003193 general anesthetic agent Substances 0.000 claims description 12
- 239000000126 substance Substances 0.000 claims description 12
- GVEAYVLWDAFXET-XGHATYIMSA-N pancuronium Chemical compound C[N+]1([C@@H]2[C@@H](OC(C)=O)C[C@@H]3CC[C@H]4[C@@H]5C[C@@H]([C@@H]([C@]5(CC[C@@H]4[C@@]3(C)C2)C)OC(=O)C)[N+]2(C)CCCCC2)CCCCC1 GVEAYVLWDAFXET-XGHATYIMSA-N 0.000 claims description 5
- 229960003819 vecuronium Drugs 0.000 claims description 5
- BGSZAXLLHYERSY-XQIGCQGXSA-N vecuronium Chemical compound N1([C@@H]2[C@@H](OC(C)=O)C[C@@H]3CC[C@H]4[C@@H]5C[C@@H]([C@@H]([C@]5(CC[C@@H]4[C@@]3(C)C2)C)OC(=O)C)[N+]2(C)CCCCC2)CCCCC1 BGSZAXLLHYERSY-XQIGCQGXSA-N 0.000 claims description 5
- MUQUYTSLDVKIOF-CHJKCJHBSA-N alcuronium Chemical compound C/1([C@@H]23)=C\N([C@H]4\5)C6=CC=CC=C6[C@]4(CC[N@@+]4(CC=C)C\C6=C\CO)[C@@H]4C[C@@H]6C/5=C/N3C3=CC=CC=C3[C@@]22CC[N@@+]3(CC=C)C/C(=C/CO)[C@@H]\1C[C@H]32 MUQUYTSLDVKIOF-CHJKCJHBSA-N 0.000 claims description 4
- 229960002428 fentanyl Drugs 0.000 claims description 4
- PJMPHNIQZUBGLI-UHFFFAOYSA-N fentanyl Chemical compound C=1C=CC=CC=1N(C(=O)CC)C(CC1)CCN1CCC1=CC=CC=C1 PJMPHNIQZUBGLI-UHFFFAOYSA-N 0.000 claims description 4
- 229960005457 pancuronium Drugs 0.000 claims description 4
- 229940120904 succinylcholine chloride Drugs 0.000 claims description 4
- YOEWQQVKRJEPAE-UHFFFAOYSA-L succinylcholine chloride (anhydrous) Chemical compound [Cl-].[Cl-].C[N+](C)(C)CCOC(=O)CCC(=O)OCC[N+](C)(C)C YOEWQQVKRJEPAE-UHFFFAOYSA-L 0.000 claims description 4
- 229930003347 Atropine Natural products 0.000 claims description 3
- -1 Gellarin Chemical compound 0.000 claims description 3
- RKUNBYITZUJHSG-UHFFFAOYSA-N Hyosciamin-hydrochlorid Natural products CN1C(C2)CCC1CC2OC(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-UHFFFAOYSA-N 0.000 claims description 3
- XADCESSVHJOZHK-UHFFFAOYSA-N Meperidine Chemical compound C=1C=CC=CC=1C1(C(=O)OCC)CCN(C)CC1 XADCESSVHJOZHK-UHFFFAOYSA-N 0.000 claims description 3
- 229960004322 alcuronium Drugs 0.000 claims description 3
- 229960000396 atropine Drugs 0.000 claims description 3
- RKUNBYITZUJHSG-SPUOUPEWSA-N atropine Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)N2C)C(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-SPUOUPEWSA-N 0.000 claims description 3
- AAOVKJBEBIDNHE-UHFFFAOYSA-N diazepam Chemical compound N=1CC(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 AAOVKJBEBIDNHE-UHFFFAOYSA-N 0.000 claims description 3
- 229960000394 droperidol Drugs 0.000 claims description 3
- RMEDXOLNCUSCGS-UHFFFAOYSA-N droperidol Chemical compound C1=CC(F)=CC=C1C(=O)CCCN1CC=C(N2C(NC3=CC=CC=C32)=O)CC1 RMEDXOLNCUSCGS-UHFFFAOYSA-N 0.000 claims description 3
- 229960003054 gallamine Drugs 0.000 claims description 3
- ICLWTJIMXVISSR-UHFFFAOYSA-N gallamine Chemical compound CCN(CC)CCOC1=CC=CC(OCCN(CC)CC)=C1OCCN(CC)CC ICLWTJIMXVISSR-UHFFFAOYSA-N 0.000 claims description 3
- 229960004315 phenoperidine Drugs 0.000 claims description 3
- IPOPQVVNCFQFRK-UHFFFAOYSA-N phenoperidine Chemical compound C1CC(C(=O)OCC)(C=2C=CC=CC=2)CCN1CCC(O)C1=CC=CC=C1 IPOPQVVNCFQFRK-UHFFFAOYSA-N 0.000 claims description 3
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 claims description 2
- 229920000609 methyl cellulose Polymers 0.000 claims description 2
- 239000001923 methylcellulose Substances 0.000 claims description 2
- 239000003158 myorelaxant agent Substances 0.000 claims description 2
- 230000001670 myorelaxant effect Effects 0.000 claims description 2
- 229960002646 scopolamine Drugs 0.000 claims description 2
- 229960003529 diazepam Drugs 0.000 claims 2
- 229960000482 pethidine Drugs 0.000 claims 2
- 229960001844 tubocurarine Drugs 0.000 claims 2
- FOKWMWSOTUZOPN-UHFFFAOYSA-N octamagnesium;iron(2+);pentasilicate Chemical compound [Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Fe+2].[Fe+2].[O-][Si]([O-])([O-])[O-].[O-][Si]([O-])([O-])[O-].[O-][Si]([O-])([O-])[O-].[O-][Si]([O-])([O-])[O-].[O-][Si]([O-])([O-])[O-] FOKWMWSOTUZOPN-UHFFFAOYSA-N 0.000 claims 1
- 239000011025 peridot Substances 0.000 claims 1
- 230000001681 protective effect Effects 0.000 claims 1
- JFJZZMVDLULRGK-URLMMPGGSA-O tubocurarine Chemical compound C([C@H]1[N+](C)(C)CCC=2C=C(C(=C(OC3=CC=C(C=C3)C[C@H]3C=4C=C(C(=CC=4CCN3C)OC)O3)C=21)O)OC)C1=CC=C(O)C3=C1 JFJZZMVDLULRGK-URLMMPGGSA-O 0.000 claims 1
- 206010020751 Hypersensitivity Diseases 0.000 abstract description 3
- 230000007815 allergy Effects 0.000 abstract description 2
- 230000009897 systematic effect Effects 0.000 abstract description 2
- 238000001514 detection method Methods 0.000 abstract 1
- 239000012213 gelatinous substance Substances 0.000 abstract 1
- 208000003455 anaphylaxis Diseases 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 239000000499 gel Substances 0.000 description 3
- 206010002091 Anaesthesia Diseases 0.000 description 2
- 206010002198 Anaphylactic reaction Diseases 0.000 description 2
- IUJDSEJGGMCXSG-UHFFFAOYSA-N Thiopental Chemical compound CCCC(C)C1(CC)C(=O)NC(=S)NC1=O IUJDSEJGGMCXSG-UHFFFAOYSA-N 0.000 description 2
- 208000026935 allergic disease Diseases 0.000 description 2
- 230000037005 anaesthesia Effects 0.000 description 2
- 238000002695 general anesthesia Methods 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 230000035939 shock Effects 0.000 description 2
- 206010002199 Anaphylactic shock Diseases 0.000 description 1
- 241000283074 Equus asinus Species 0.000 description 1
- PPTYJKAXVCCBDU-UHFFFAOYSA-N Rohypnol Chemical compound N=1CC(=O)N(C)C2=CC=C([N+]([O-])=O)C=C2C=1C1=CC=CC=C1F PPTYJKAXVCCBDU-UHFFFAOYSA-N 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000009610 hypersensitivity Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 235000015110 jellies Nutrition 0.000 description 1
- 239000008274 jelly Substances 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 238000004370 retrospective diagnosis Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 229960003279 thiopental Drugs 0.000 description 1
- 229940072690 valium Drugs 0.000 description 1
- VEPSYABRBFXYIB-PWXDFCLTSA-M vecuronium bromide Chemical compound [Br-].N1([C@@H]2[C@@H](OC(C)=O)C[C@@H]3CC[C@H]4[C@@H]5C[C@@H]([C@@H]([C@]5(CC[C@@H]4[C@@]3(C)C2)C)OC(=O)C)[N+]2(C)CCCCC2)CCCCC1 VEPSYABRBFXYIB-PWXDFCLTSA-M 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods
- A61B17/20—Surgical instruments, devices or methods for vaccinating or cleaning the skin previous to the vaccination
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Surgery (AREA)
- Heart & Thoracic Surgery (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medical Informatics (AREA)
- Molecular Biology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
TESTS CUTANES AUX ANESTHESIQUES. SKIN TESTS WITH ANESTHETICS.
La présente invention a trait à un nouveau test cutané aux anesthésiques. The present invention relates to a new skin test for anesthetics.
Le problème des réactions et chocs anaphylactiques, lors d'inductions anesthésiques comportant notamment des curarisants, représente un problème important en raison de sa fréquence (1/4000 anesthésies environ) et grave puisqu'ils constituent, probablement, la principale cause de mortalité par allergie médicamenteuse. The problem of anaphylactic reactions and shocks, during anesthetic induction including curarisants, is a significant problem because of its frequency (about 1/4000 anesthesia) and serious since they are probably the main cause of death from allergy medicated.
Actuellement, le diagnostic rétrospectif s'effectue grâce a des intradermoréactions de quantités minimes de l'anesthésique suspecté. Par contre, il n'existe aucun moyen d'effectuer des tests cutanés de façon prédictive, et l'utilisation de ces intradermoréactions à grande échelle par les anesthésistes et les infirmières est exclue pour des raisons pratiques. Currently, retrospective diagnosis is carried out using intradermal reactions of minimal quantities of the suspected anesthetic. On the other hand, there is no way to perform skin tests predictively, and the use of these intradermal reactions on a large scale by anesthesiologists and nurses is excluded for practical reasons.
La présente invention se propose de remédier a ces inconvénients et de fournir un test cutané aux anes thétiques qui permette de faire des tests prédictifs, permettant de déceler les sujets à risques avant une intervention mettant en oeuvre une anesthésie générale. The present invention proposes to remedy these drawbacks and to provide a skin test for cosmetic donkeys which makes it possible to make predictive tests, making it possible to detect subjects at risk before an intervention using general anesthesia.
Un autre objectif de l'invention est de fournir un tel test qui soit extrêmement simple à utiliser, et qui se prête donc a un dépistage systématique pre-opératoire. Another object of the invention is to provide such a test which is extremely simple to use, and which therefore lends itself to systematic pre-operative screening.
Un autre objectif de l'invention est de réaliser un tel test qui soit peu coûtent et de mise en oeuvre extrêmoment simple. Another objective of the invention is to carry out such a test which is inexpensive and extremely simple to implement.
L'invention a pour objet un test cutané aux anesthésiques, caractérisé en ce qu'il comporte une pointe de micropiqfire reliée a un organe de préhension permettant sa manipulation, ladite pointe étant chargée de l'anesthési- que suspect a concentration usuelle, ledit anesthésique étant, de préférence, incorporé dans une substance géliforme. The subject of the invention is a skin test with anesthetics, characterized in that it comprises a micropiqfire tip connected to a gripping member allowing its manipulation, said tip being charged with suspect anesthetic at usual concentration, said anesthetic. preferably being incorporated into a gel-like substance.
L'invention a également pour objet, a titre de préparation nouvelle, des gels d'anesthésique et notamment d'anesthésique curarisant, caractérisés en ce qu'ils sont composés d'un anesthésique à concentration usuelle et d'une substance géliforme. The subject of the invention is also, as a new preparation, anesthetic and in particular curarizing anesthetic gels, characterized in that they are composed of an anesthetic at usual concentration and of a gel-like substance.
Cette substance est de préférence un gel de méthylcellulose auquel on peut éventuellement ajouter du glycérol et du phénol. This substance is preferably a methylcellulose gel to which glycerol and phenol can optionally be added.
Par concentration usuelle dans le sens de la présente invention, on entend une concentration d'anesthésique de l'ordre de la préparation anesthésique vendue dans le commerce et donc supérieure, en général, aux concentrations que l'on utilise pour des intradermoréactions, sous forme de séries de dilutions décroissantes, pour le même anesthésique. By usual concentration in the sense of the present invention means a concentration of anesthetic of the order of the anesthetic preparation sold on the market and therefore higher, in general, than the concentrations that are used for intradermal reactions, in the form decreasing dilution series for the same anesthetic.
Les anesthésiques mis en oeuvre dans la présente invention sont notamment les suivants (la marque précède la dénomination commune) (NORCURON) VECURONIUM (DROLEPTAN) DROPERIDOL (ALLOFERINE) ALCURONIUM ATROPINE (CELOCURINE) SUXAMETHONIUM (DOLOSAL) CHLORHYDRATE DE (FENTANYL) FENTANYL PETHIDINE (FLAXEDIL) GALLAMINE (SEDOL) Association morphi
ne-scopolamine (PAVULON) PANCURONIUM (VALIUM) DIAPEZAM (NESDONAL) PENTHOTAL PHENOPERIDINE
(NARCOZEP)
D-TUBOCURARI NE
SUCCINCURARIUM
De facon avantageuse, le test cutané selon l'invention peut comporter un dispositif scarificateur a micrcpiqu- re contenant une seule pointe tel que décrit, par exemple.The anesthetics used in the present invention are notably the following (the mark precedes the common name) (NORCURON) VECURONIUM (DROLEPTAN) DROPERIDOL (ALLOFERINE) ALCURONIUM ATROPINE (CELOCURINE) SUXAMETHONIUM (DOLOSAL) CHLORHYDRATE OF (FENTANYL) ) GALLAMINE (SEDOL) Association morphi
ne-scopolamine (PAVULON) PANCURONIUM (VALIUM) DIAPEZAM (NESDONAL) PENTHOTAL PHENOPERIDINE
(NARCOZEP)
D-TUBOCURARI NE
SUCCINCURARIUM
Advantageously, the skin test according to the invention may include a microscopic scarifier device containing a single point as described, for example.
dans la demande de brevet français n0 82 18583 déposée le 5 nbvembre 1982.in French patent application No. 82 18583 filed on November 5, 1982.
En variante, on peut également utiliser des scarifi ateurs comprenant une pluralité de groupes de pointes espacées les uns des autres, chaque groupe présentant de préférence une seule pointe, comme décrit par exemple dans le brevet français n0 2 474 856 déposé le 31 janvier 1980. As a variant, it is also possible to use scarifiers comprising a plurality of groups of points spaced from each other, each group preferably having a single point, as described for example in French patent No. 2,474,856 filed on January 31, 1980.
De préférence, la pointe du scarificateur est imrégnée a l'avance de la gelée comportant l'anesthésique et, dans ce cas, on peut avantageusement protéger la pointe, jusqu'S son usage, en l'entourant d'une enveloppe amovible comme décrit, par exemple, dans le brevet français nc 2 r' 856 Drrité. Preferably, the tip of the scarifier is impregnated in advance with the jelly comprising the anesthetic and, in this case, the tip can advantageously be protected, until it is used, by surrounding it with a removable envelope as described, by example, in French patent nc 2 r '856 Druité.
En dehors du caractère systematiquement prédictif cue l'on peut obtenir grace a l'invention, on Z constaté cue les tests cutanés selon l'invention permettent d'éviter des inconvénients présentés par les tests d'intradermoréaction classiques aux anesthésiques et notamment les risques de choc. Le test selon l'invention peut être mis en oeuvre beaucoup plus rapidement et permet de constituer facilement un témoin. En outre, le test demande une seule mise en oeuvre contrairement a l'intradermoréaction qui demande une série d'injections intradermiques a teneur croissante en anesthésique. Apart from the systematically predictive nature which can be obtained by virtue of the invention, it has been found that the skin tests according to the invention make it possible to avoid the drawbacks presented by the conventional intradermal reaction tests with anesthetics and in particular the risks of shock. The test according to the invention can be implemented much more quickly and makes it possible to easily constitute a control. In addition, the test requires only one implementation unlike intradermoreaction which requires a series of intradermal injections with increasing anesthetic content.
D'autres avantages et caractéristiques de l'invention apparaitront a la lecture de la description suivante, faite à titre d'exemple non limitatif. Other advantages and characteristics of the invention will appear on reading the following description, given by way of nonlimiting example.
Les scarificateurs utilisés dans la description suivante sont du type décrit dans la demande de brevet fran çais n 82 18583 déposée le 5 novembre 1982. Ils présentent les caractéristiques dimensionnelles suivantes :
Longueur de la pointe Conicité
Présence d'un évidement dans la pointe
Forme de la section de la pointe :
Préparation d'un gel Incorporant 11 anesthésique
On mélange, a température ambiante de 0,5 a 58 de methylallulose, 1 å 50% de glycérol, le reste -étant constitube de la solution commerciale de l'anesthésique choisi.The scarifiers used in the following description are of the type described in French patent application No. 82 18583 filed on November 5, 1982. They have the following dimensional characteristics:
Tip length Taper
Presence of a recess in the tip
Shape of the tip section:
Preparation of a gel incorporating 11 anesthetic
One mixes, at room temperature from 0.5 to 58 of methylallulose, 1 to 50% of glycerol, the remainder constituting the commercial solution of the chosen anesthetic.
Par exemple : methylallulose 4 %
Glycérol 41 %
VECURONIUM 55 %.For example: methylallulose 4%
Glycerol 41%
VECURONIUM 55%.
Essais cliniques
Les essais ont été effectués sur quatre groupes.Clinical tests
The tests were carried out on four groups.
Le groupe 1 était composé de 50 patients ayant subi une réaction anaphylactique dans les 10 mn suivant l'injection des anesthésiques. Ils avaient tous ensuite été soumis a une intradermoréaction aux anesthésiques suspectes et l'intradermoréaction avait été positive pour l'un au moins des anesthésiques chez chacun.Group 1 consisted of 50 patients who underwent an anaphylactic reaction within 10 minutes of the injection of the anesthetics. They were all then subjected to a skin test for suspect anesthetics and the skin test was positive for at least one of the drugs in each.
Le groupe 2 était constitué de 7 patients ayant également eu une réaction anaphylactique dans les 10 mn suivant l'injection des anesthésiques. Ces patients nta- vaient pas subi d'intradermoreaction rétrospective. Group 2 consisted of 7 patients who also had an anaphylactic reaction within 10 minutes of injecting the anesthetics. These patients did not undergo retrospective intradermoreaction.
Le groupe 3 était compose de 6 patients ayant eu des réactions non anaphylactiques durant l'anesthésie. Ils avaient ensuite été testés par intradermoréaction avec des résultats négatifs. Group 3 consisted of 6 patients who had non-anaphylactic reactions during anesthesia. They were then tested by intradermoreaction with negative results.
Le groupe 4 constituait le groupe témoin et était compose de 16 employés de l'hopital. 12 d'entre eux avaient été anesthésiés sans effets secondaires. Group 4 was the control group and consisted of 16 hospital staff. 12 of them had been anesthetized with no side effects.
Les substances testées étaient 5 myo-relaxants, a savoir suxamethonium, gallamine, alcuronium, pancuronium, vecuronium, et deux autres anesthésiques fentanyl et thiopental. Les patients ont tous subi d'une part la batterie des intradermoréactions usuelles et d'autre part les tests cutanés selon l'invention. The substances tested were myo-relaxants, namely suxamethonium, gallamine, alkuronium, pancuronium, vecuronium, and two other anesthetics fentanyl and thiopental. The patients all underwent on the one hand the battery of the usual intradermal reactions and on the other hand the skin tests according to the invention.
Résultats
On a pu constater, chez ceux des patients (groupes 1 et 3) qui avaient déja subi des tests intradermiques aux anesthésiques, une variation des résultats du nouveau test par rapport a ceux de l'ancien test intradermique. En fait, les test sont devenus négatifs dans 30 % des cas.Results
It was found that in those patients (groups 1 and 3) who had already undergone intradermal anesthetic tests, the results of the new test varied from those of the old intradermal test. In fact, the tests became negative in 30% of the cases.
On a obtenu une concordance très significative entre les tests selon l'invention et les résultats des intradermoréactions (97,3 % p inférieur a 0,001) et les diamètres des tests montraient une corrélation significative. A very significant agreement was obtained between the tests according to the invention and the results of the intradermoreactions (97.3% p less than 0.001) and the diameters of the tests showed a significant correlation.
Les tests selon l'invention peuvent donc être considérés comme particulièrement utiles pour déceler l'état d'hypersensibilité aux anesthésiques considérés a condition d'être effectués sur les patients très peu de temps avant l'anesthésie générale projetée. The tests according to the invention can therefore be considered to be particularly useful for detecting the state of hypersensitivity to the anesthetics considered, provided that they are carried out on patients very shortly before the planned general anesthesia.
Ils peuvent être systématiquement mis en oeuvre de façon simple par les anesthésistes ou les infirmières. They can be systematically implemented in a simple way by anesthesiologists or nurses.
Claims (10)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR8602561A FR2594683A1 (en) | 1986-02-25 | 1986-02-25 | Skin tests for anaesthetics |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR8602561A FR2594683A1 (en) | 1986-02-25 | 1986-02-25 | Skin tests for anaesthetics |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| FR2594683A1 true FR2594683A1 (en) | 1987-08-28 |
Family
ID=9332493
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FR8602561A Withdrawn FR2594683A1 (en) | 1986-02-25 | 1986-02-25 | Skin tests for anaesthetics |
Country Status (1)
| Country | Link |
|---|---|
| FR (1) | FR2594683A1 (en) |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2866452A (en) * | 1957-03-11 | 1958-12-30 | Ernest S V Laub | Allergen applicators |
| US3291129A (en) * | 1962-08-10 | 1966-12-13 | Burelle Pierre Laurent Raymond | Scarificator for use in vaccination, skin tests, or the like |
| GB2068236A (en) * | 1980-01-31 | 1981-08-12 | Merieux Inst | Scarifier |
| FR2535602A1 (en) * | 1982-11-05 | 1984-05-11 | Stallergenes Lab | Scarifying device |
| US4474752A (en) * | 1983-05-16 | 1984-10-02 | Merck & Co., Inc. | Drug delivery system utilizing thermosetting gels |
-
1986
- 1986-02-25 FR FR8602561A patent/FR2594683A1/en not_active Withdrawn
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2866452A (en) * | 1957-03-11 | 1958-12-30 | Ernest S V Laub | Allergen applicators |
| US3291129A (en) * | 1962-08-10 | 1966-12-13 | Burelle Pierre Laurent Raymond | Scarificator for use in vaccination, skin tests, or the like |
| GB2068236A (en) * | 1980-01-31 | 1981-08-12 | Merieux Inst | Scarifier |
| FR2535602A1 (en) * | 1982-11-05 | 1984-05-11 | Stallergenes Lab | Scarifying device |
| US4474752A (en) * | 1983-05-16 | 1984-10-02 | Merck & Co., Inc. | Drug delivery system utilizing thermosetting gels |
Non-Patent Citations (3)
| Title |
|---|
| J. ALLERGY CLIN. IMMUNOL., vol. 63, no. 6, juin 1979, pages 387-394; R.D.deSHAZO et al.: "An approach to the patient with a history of local anesthetic hypersensitivity: Experience with 90 patients" * |
| J. ALLERGY CLIN. IMMUNOL., vol. 71, no. 6, juin 1983, pages 552-559; D.VERVLOET et al.: "Adverse reactions to suxamethonium and other muscle relaxants under general anesthesia" * |
| LA NOUVELLE PRESSE MEDICALE, vol. 6, no. 9, 5 mars 1977, pages 725-728; D.VERVLOET et al.: "Accidents de type anaphylactique imputables aux myorelaxants au cours de l'anesthésie générale" * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Sawada et al. | Estrogen receptor antagonist ICI182, 780 exacerbates ischemic injury in female mouse | |
| Sim et al. | Pain on injection with microemulsion propofol | |
| Keller et al. | Protective effect of halothane anesthesia on retinal light damage: inhibition of metabolic rhodopsin regeneration | |
| Sandoval et al. | Methylphenidate alters vesicular monoamine transport and prevents methamphetamine-induced dopaminergic deficits | |
| Andoh et al. | Nociceptin gene expression in rat dorsal root ganglia induced by peripheral inflammation | |
| Arendash et al. | Environmental enrichment improves cognition in aged Alzheimer's transgenic mice despite stable β-amyloid deposition | |
| Kim et al. | Ketone bodies are protective against oxidative stress in neocortical neurons | |
| Gunnett et al. | Interleukin-10 Protects Nitric Oxide–Dependent Relaxation During Diabetes: Role of Superoxide | |
| Boyko et al. | Pyruvate’s blood glutamate scavenging activity contributes to the spectrum of its neuroprotective mechanisms in a rat model of stroke | |
| Langdon et al. | Persistent behavioral impairments and neuroinflammation following global ischemia in the rat | |
| Barra et al. | Localized immunosuppression with tannic acid encapsulation delays islet allograft and autoimmune-mediated rejection | |
| Stork et al. | Rising zinc: a significant cause of ischemic neuronal death in the CA1 region of rat hippocampus | |
| Zheng et al. | Uninephrectomy of diabetic OVE26 mice greatly accelerates albuminuria, fibrosis, inflammatory cell infiltration and changes in gene expression | |
| Vieira et al. | Lupus erythematosus tumidus: a series of 26 cases | |
| Lin et al. | Multifaceted effects of astragaloside IV on promotion of random pattern skin flap survival in rats | |
| Zhou et al. | Self‐Propelled Ultrasmall AuNPs‐Tannic Acid Hybrid Nanozyme with ROS‐Scavenging and Anti‐Inflammatory Activity for Drug‐Induced Liver Injury Alleviation | |
| Andersen et al. | Antipruritic effect of pretreatment with topical capsaicin 8% on histamine‐and cowhage‐evoked itch in healthy volunteers: a randomized, vehicle‐controlled, proof‐of‐concept trial | |
| Kaur et al. | Neonatal pig Sertoli cells survive xenotransplantation by creating an immune modulatory environment involving CD4 and CD8 regulatory T cells | |
| McPherson et al. | Altered renal hemodynamics is associated with glomerular lipid accumulation in obese Dahl salt-sensitive leptin receptor mutant rats | |
| FR2594683A1 (en) | Skin tests for anaesthetics | |
| Sugawara et al. | Candesartan reduces superoxide production after global cerebral ischemia | |
| Delic et al. | Loss of ability to self-heal malaria upon taurine transporter deletion | |
| Schwinn et al. | Understanding the TXA seizure connection | |
| Park et al. | Calpain inhibition attenuated morphological and molecular changes in skeletal muscle of experimental allergic encephalomyelitis rats | |
| Colbourne et al. | Spontaneous postischemic hyperthermia is not required for severe CA1 ischemic damage in gerbils |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| ST | Notification of lapse |